Leading with expertise and vision, our management team is dedicated to advancing pharmaceutical solutions, fostering innovation, and ensuring operational excellence to achieve impactful health outcomes worldwide.
Over 25 years of international experience in the biotechnology sector, spanning drug discovery, development, and investment.
Former CEO of Vesper Bio, where he advanced programs from discovery to clinical Phase II, and Board Director at Folium.
Previously Operating Partner at the Lundbeck Foundation, supporting and building innovative life science ventures across Europe.
Holds a PhD in Organic Chemistry from Cardiff University and a BSc in Chemistry from the University of Nottingham, and a Fellow of the Royal Society of Chemistry.
Over 27 years of executive experience in the life science sector, serving as a Chief Financial Officer since 2001.
Proven track record as CFO for five companies listed on Nasdaq Stockholm: three in Life Science (Recipharm, Bonesupport, SynAct Pharma) and two in the IT sector (Jeeves, Enea).
Foundational career experience at AstraZeneca (1989–2001), where he held a variety of key positions.
